137 related articles for article (PubMed ID: 28509586)
1. Long-term persistent donor-recipient mixed chimerism without disease recurrence after myeloablative single-unit cord blood transplantation in adult acute myeloid leukemia following myelodysplastic syndrome.
Tanoue S; Konuma T; Takahashi S; Watanabe E; Sato N; Watanabe N; Isobe M; Kato S; Ooi J; Tojo A
Leuk Lymphoma; 2017 Dec; 58(12):2973-2975. PubMed ID: 28509586
[No Abstract] [Full Text] [Related]
2. Cord blood chimerism and relapse after haplo-cord transplantation.
van Besien K; Koshy N; Gergis U; Mayer S; Cushing M; Rennert H; Reich-Slotky R; Mark T; Pearse R; Rossi A; Phillips A; Vasovic L; Ferrante R; Hsu YM; Shore T
Leuk Lymphoma; 2017 Feb; 58(2):288-297. PubMed ID: 27333804
[TBL] [Abstract][Full Text] [Related]
3. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Lee HC; Saliba RM; Rondon G; Chen J; Charafeddine Y; Medeiros LJ; Alatrash G; Andersson BS; Popat U; Kebriaei P; Ciurea S; Oran B; Shpall E; Champlin R
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1948-54. PubMed ID: 26183077
[TBL] [Abstract][Full Text] [Related]
4. The impact of pre-transplant minimal residual disease on outcome of intensified myeloablative cord blood transplant for acute myeloid leukemia in first or second complete remission.
Zheng C; Zhu X; Tang B; Zhang L; Geng L; Liu H; Sun Z
Leuk Lymphoma; 2016; 57(6):1398-405. PubMed ID: 26690538
[TBL] [Abstract][Full Text] [Related]
5. Early engraftment and full-donor chimerism after single-cord blood plus third-party donor dual transplantation in patients with high-risk acute leukemia.
Sánchez-Ortega I; Arnan M; Patiño B; Herrero MJ; Querol S; Duarte RF
Bone Marrow Transplant; 2014 Jan; 49(1):145-7. PubMed ID: 23933757
[No Abstract] [Full Text] [Related]
6. Early phase mixed chimerism in bone marrow does not affect long-term outcomes of myeloablative single-unit cord blood transplantation for adult patients with hematological malignancies.
Konuma T; Kato S; Oiwa-Monna M; Ishii H; Tojo A; Takahashi S
Leuk Lymphoma; 2016 Dec; 57(12):2848-2854. PubMed ID: 27124418
[TBL] [Abstract][Full Text] [Related]
7. Unrelated cord blood transplantation and post-transplant cyclophosphamide.
Bacigalupo A; Sica S; Laurenti L; Sora' F; Giammarco S; Metafuni E; Innocenti I; Autore F; Teofili L; Bianchi M; Chiusolo P
Haematologica; 2019 Feb; 104(2):e77-e78. PubMed ID: 30573505
[No Abstract] [Full Text] [Related]
8. A Study of Human Leukocyte Antigen Mismatched Cellular Therapy (Stem Cell Microtransplantation) in High-Risk Myelodysplastic Syndrome or Transformed Acute Myelogenous Leukemia.
Hu KX; Sun QY; Guo M; Qiao JX; Yu CL; Qiao JH; Dong Z; Sun WJ; Zuo HL; Huang YJ; Cai B; Ai HS
Stem Cells Transl Med; 2016 Apr; 5(4):524-9. PubMed ID: 26838271
[TBL] [Abstract][Full Text] [Related]
9. Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
Davies JK; Hassan S; Sarker SJ; Besley C; Oakervee H; Smith M; Taussig D; Gribben JG; Cavenagh JD
Br J Haematol; 2018 Feb; 180(3):346-355. PubMed ID: 29076145
[TBL] [Abstract][Full Text] [Related]
10. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis.
Scott BL; Sandmaier BM; Storer B; Maris MB; Sorror ML; Maloney DG; Chauncey TR; Storb R; Deeg HJ
Leukemia; 2006 Jan; 20(1):128-35. PubMed ID: 16270037
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Limitations of Donor T Cell Chimerism after Myeloablative Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Wong E; Mason K; Collins J; Hockridge B; Boyd J; Gorelik A; Szer J; Ritchie DS
Biol Blood Marrow Transplant; 2017 May; 23(5):840-844. PubMed ID: 28167152
[TBL] [Abstract][Full Text] [Related]
12. Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older.
Konuma T; Tsukada N; Kanda J; Uchida N; Ohno Y; Miyakoshi S; Kanamori H; Hidaka M; Sakura T; Onizuka M; Kobayashi N; Sawa M; Eto T; Matsuhashi Y; Kato K; Ichinohe T; Atsuta Y; Miyamura K;
Am J Hematol; 2016 May; 91(5):E284-92. PubMed ID: 26910296
[TBL] [Abstract][Full Text] [Related]
13. Hyperacute graft-vs.-host disease after related HLA-identical umbilical cord blood transplantation.
Kuskonmaz B; Gocer S; Ersoy-Ewans S; Cetin Ozman F; Cetin M; Uckan D
Pediatr Transplant; 2007 Nov; 11(7):818-20. PubMed ID: 17910666
[TBL] [Abstract][Full Text] [Related]
14. Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion.
Eefting M; de Wreede LC; Halkes CJ; von dem Borne PA; Kersting S; Marijt EW; Veelken H; Putter H; Schetelig J; Falkenburg JH
Haematologica; 2016 Apr; 101(4):506-14. PubMed ID: 26802054
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic hematopoietic stem cell transplant overcomes poor prognosis of acute myeloid leukemia with myelodysplasia-related changes.
Ikegawa S; Doki N; Kurosawa S; Yamaguchi T; Sakaguchi M; Harada K; Yamamoto K; Hino Y; Shingai N; Senoo Y; Watanabe K; Igarashi A; Najima Y; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
Leuk Lymphoma; 2016; 57(1):76-80. PubMed ID: 26084204
[TBL] [Abstract][Full Text] [Related]
16. Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome.
Bernal T; Diez-Campelo M; Godoy V; Rojas S; Colado E; Alcoceba M; González M; Vidriales B; Sánchez-Guijo FM; López-Corral L; Luño E; del Cañizo C
Leuk Res; 2014 May; 38(5):551-6. PubMed ID: 24655806
[TBL] [Abstract][Full Text] [Related]
17. Single-unit cord blood transplantation after granulocyte colony-stimulating factor-combined myeloablative conditioning for myeloid malignancies not in remission.
Konuma T; Kato S; Ooi J; Oiwa-Monna M; Ebihara Y; Mochizuki S; Yuji K; Ohno N; Kawamata T; Jo N; Yokoyama K; Uchimaru K; Asano S; Tojo A; Takahashi S
Biol Blood Marrow Transplant; 2014 Mar; 20(3):396-401. PubMed ID: 24333750
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic hematopoietic cell transplantation in morphologic leukemia-free aplastic state.
Rashidi A; Ali AM; Vij KR; Shanley R; Romee R; Cooley SA; Westervelt P; DiPersio JF; Miller JS; Weisdorf DJ; Ustun C
Am J Hematol; 2017 Sep; 92(9):E549-E552. PubMed ID: 28568483
[No Abstract] [Full Text] [Related]
19. [Application of chimerism analysis to allogeneic hematopoietic stem cell transplantation by STR-PCR].
Sun JF; Han XP; Zhao DD; Wang FF; Jin HJ; Gao CJ; DA WM; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):337-41. PubMed ID: 17493343
[TBL] [Abstract][Full Text] [Related]
20. Best allogeneic transplantation approach for AML patients in first CR: is delayed unrelated donor bone marrow transplantation better than immediate unrelated cord blood transplantation?
Baron F; Nagler A
Eur J Haematol; 2016 Sep; 97(3):215-6. PubMed ID: 26865252
[No Abstract] [Full Text] [Related]
[Next] [New Search]
